10% OFF Crypto | 3rd Party Tested | FREE Worldwide Shipping $400+ ($750+ for USA)
Menu
Cart
tirzepatide lyophilized peptide vial
edgepeptides tirzepatide 30mg janoshik test
edgepeptides tirzepatide 15mg janoshik test
edge peptides tirzepatide 60 mg janoshik test
edge peptides tirzepatide 10mg janoshik test
edgepeptides tirzepatide 5 mg chromate test
lyophilized peptide vial box (blue cap)

Tirzepatide 10-60mg | 10 Vial Box

Price range: $340.0 through $950.0

Buy tirzepatide 10, 15, 30, 45, or 60 mg (one 10-vial box). Worldwide dispatch 7 -14 days to the USA, UK, CA, AUS & NZ. All orders are shipped wholesale in unbranded packaging.

Bulk discounts
Quantity Bulk Discount Price
210%$306.0
3-515%$289.0
6-1020%$272.0
SKU: TIRZ Category:

Description

Tirzepatide is a peptide that helps regulate blood sugar levels and support weight management by mimicking natural hormones that control appetite and glucose balance. It’s studied for its role in promoting weight loss and improving glycemic control in type 2 diabetes patients.

Not for human use; research use only.

Minimum order quantity: one box (10 vials x 10 – 60 mg, 100-600 mg in total).

Note: Product images show branded labels for illustration purposes only. All peptides are shipped in wholesale, unbranded packaging. You can see an actual example photo of the peptide vials and container above.

Additional information

Purity

≥99.0%
Molar Mass

4813.527 g·mol
Molecular Formula

C₂₂₅H₃₄₈N₄₈O₆₈
Sequence

H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(Eicosanedioyl-isoGlu-PEG2-PEG2)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Strength

10MG, 15MG, 20MG, 30MG, 45MG, 60MG
  1. Min, Thinzar, and Stephen C. Bain. "The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials." Diabetes Therapy 12.1 (2021): 143-157.
  2. Jastreboff, Ania M., et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine 387.3 (2022): 205-216.
  3. Frías, Juan P., et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." New England Journal of Medicine 385.6 (2021): 503-515.
  4. Syed, Yahiya Y. "Tirzepatide: first approval." Drugs 82.11 (2022): 1213-1220.
  5. Rosenstock, Julio, et al. "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial." The Lancet 398.10295 (2021): 143-155.
  6. Rosenstock, Julio, et al. "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial." The Lancet 398.10295 (2021): 143-155.
  7. Chavda, Vivek P., et al. "Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review." Molecules 27.13 (2022): 4315.

Tirzepatide 5mg Chromate Test (2025)

Tirzepatide CoA

Tirzepatide HPLC

Tirzepatide 10mg Janoshik Test (2025)

Tirzepatide 60mg Janoshik Test (2025)

Tirzepatide 15mg Janoshik Test (Oct. 2025)

Tirzepatide 30mg Janoshik Test (Nov. 2025)

Related products